Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,437,395 papers from all fields of science
Search
Sign In
Create Free Account
lucatumumab
A fully human monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Lucatumumab binds to and…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Antibodies, Monoclonal, Humanized
antigen binding
Narrower (1)
monoclonal antibody CHIR-12.12
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Emerging antibodies for the treatment of multiple myeloma
F. Zagouri
,
E. Terpos
,
E. Kastritis
,
M. Dimopoulos
Expert Opinion on Emerging Drugs
2016
Corpus ID: 25871129
ABSTRACT Introduction: Monoclonal antibodies mark the beginning of a new era in the context of multiple myeloma (MM) treatment…
Expand
Review
2016
Review
2016
Activity of the CD40 antagonistic antibody lucatumumab – insights from CLL-niche mimicking xenografts and fludarabine combinations
Marius Stiefelhagen
,
Carola Gigel
,
+5 authors
M. Herling
Leukemia and Lymphoma
2016
Corpus ID: 3836742
With great interest, we read the report by Byrd et al. [1] in this journal about lucatumumab (HCD122, formerly CHIR-12.12) in…
Expand
2011
2011
Multi-Trial Safety Evaluation of the Fully Antagonistic Human Anti-CD40 Monoclonal Antibody Lucatumumab (HCD122) in Patients with Relapsed or Refractory B-Cell Malignancies,
M. Fanale
,
W. Bensinger
,
+4 authors
A. Freedman
2011
Corpus ID: 58570550
Abstract 3702 Introduction. Patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), non-Hodgkin lymphoma (NHL…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE